SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) December 23, 2004
aaiPharma Inc.
| Delaware | 0-21185 | 04-2687849 | ||
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
2320 Scientific Park Drive
Wilmington, North Carolina 28405
(910) 254-7000
Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
| o | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4c)) |
Item 7.01.Regulation FD Disclosure.
On December 23, 2004, aaiPharma Inc. (the “registrant”) issued a press release announcing that SICOR Pharmaceuticals, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd., has reacquired its U.S. marketing rights for calcitriol injection in exchange for certain payments to the registrant. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01.Financial Statements and Exhibits.
(c) Exhibits
| Exhibit 99.1 | Press release of aaiPharma Inc. dated December 23, 2004 announcing the reacquisition by SICOR Pharmaceuticals, Inc. of its U.S. marketing rights for calcitriol injection |
***
Note: The information contained in Exhibit 99.1 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 23, 2004
| aaiPharma Inc. | ||||
| By: | /s/ Matthew E. Czajkowski | |||
| Matthew E. Czajkowski, Chief Financial Officer | ||||
3
Exhibit Index
| Exhibit | Description | |
| Exhibit 99.1 | Press release of aaiPharma Inc. dated December 23, 2004 announcing the reacquisition by SICOR Pharmaceuticals, Inc. of its U.S. marketing rights for calcitriol injection |
4